Compared with proton pump inhibitor (PPI) therapy, magnetic sphincter augmentation (MSA) was far superior for reducing regurgitation in regurgitative gastroesophageal reflux disease (GERD), and relief is sustained over 12 months.
In most cases of diagnostic esophagogastroduodenoscopy (EGD) performed for refractory gastro-esophageal reflux disease (GERD), symptoms alone did not result in pathological findings that prompted a change in the patient’s GERD management.
Eosinophilic esophagitis (EoE) is a clinicopathologic disease for which proton pump inhibitors (PPIs) are now considered a treatment option. Of children with EoE, 32% responded to high-dose proton pump inhibitor (HDPPI) therapy.
EoE activity rapidly recurred after initial response to oral viscous budesonide (OVB) or fluticasone from a multidose inhaler (MDI), indicating the need for maintenance therapy for patients who achieve histologic response to topical steroids.
CVS is the latest drugstore chain to stop selling over-the-counter Zantac (ranitidine), as well as the store’s own generic version of the heartburn medicine, because of contamination with a known carcinogen.